Ignite Creation Date:
2025-12-25 @ 1:12 AM
Ignite Modification Date:
2025-12-25 @ 11:22 PM
Study NCT ID:
NCT05482893
Status:
RECRUITING
Last Update Posted:
2025-11-04
First Post:
2022-07-25
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Sponsor:
Phanes Therapeutics
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-03-15
Start Date Type:
ACTUAL
Primary Completion Date:
2027-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-04
Completion Date Type:
ESTIMATED
First Submit Date:
2022-07-25
First Submit QC Date:
None
Study First Post Date:
2022-08-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-31
Last Update Post Date:
2025-11-04
Last Update Post Date Type:
ESTIMATED